Fresh Frozen Facts Part 4: A Thoughtful Look at Plasma Transfusion by Dr. Caitlin Raymond
Caitlin Raymond, MD/PhD shared an insightful chain of posts on LinkedIn:
”Fresh Frozen Facts, Part IV: Beyond the Blood Bag
We’ve spent the last three posts unpacking the nuances of plasma as a transfusion product — thawed, typed, and delivered with varying degrees of clarity and clinical intent. But plasma’s story doesn’t stop there.
In Part IV, we explore what happens after donation — when plasma is fractionated, purified, and turned into targeted biologics that power modern hematology, neurology, rheumatology, immunology, and more.
From albumin for oncotic support to IVIG for immune modulation and Rh immune globulin for alloimmunization prevention, these plasma-derived therapies are more than just “blood products.” They’re precision tools — crafted for specific indications and held to pharmaceutical-grade standards.
We cover:
- Albumin: when it’s the right choice — and when it isn’t
- IVIG: how it works, when to use it, and key risks to know
- RhIg: an elegant triumph of targeted immunotherapy
- Hyperimmune globulins, antithrombin, C1 esterase inhibitor, and more
- The evolving landscape of patient-centered transfusion, including care for Jehovah’s Witnesses and the legacy of hemophilia and HIV
This final installment is about precision, stewardship, and respect — for the science and the people behind every plasma product.
And if you’ve missed the earlier parts of the series, now’s the time to catch up.
Because transfusion medicine doesn’t end with a blood bag — and sometimes the most powerful plasma products don’t look like blood at all.
Read the full post here.
Caitlin Raymond, MD/PhD, has launched an educational series on Fresh Frozen Plasma (FFP), now available on her journal blog.
Enjoy the final part and make sure you do not miss all the Fresh Frozen Facts!
Stay tuned for updates to the Fresh Frozen Facts series on Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome